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Purpose
To address gaps in evidence on the risk of cancer in people from sexual minorities.
Patients and Methods
Weused data from 796,594 population-based English General Practice Patient Survey responders to
explore the prevalence of self-reported diagnoses of cancer in the last 5 years among sexual
minorities compared with heterosexual women and men. We analyzed data from 249,010 hospital-
based English Cancer Patient Experience Survey responders with sexual orientation as a binary
outcome, and International Classification of Diseases, Tenth, Revision, diagnosis as covariate—38
different common and rarer cancers, with breast and prostate cancer as baseline categories for
women and men, respectively—to examine whether people from sexual minorities are over- or
under-represented among different cancer sites. For both analyses, we used logistic regression,
stratified by sex and adjusted for age.
Results
A diagnosis of cancer in the past 5 years was more commonly reported by male General Practice
Patient Survey responders who endorsed gay or bisexual orientation compared with heterosexual
men (odds ratio [OR], 1.31; 95%CI, 1.15 to 1.49; P, .001) without evidence of a difference between
lesbian or bisexual compared with heterosexual women (OR, 1.14; 95% CI, 0.94 to 1.37; P = .19).
For most common and rarer cancer sites (30 of 33 in women, 28 of 32 in men), the odds of specific
cancer site diagnosis among Cancer Patient Experience Survey respondents seemed to be in-
dependent of sexual orientation; however, there were notable differences in infection-related (HIV
and human papillomavirus [HPV]) cancers. Gay or bisexual men were over-represented among men
with Kaposi’s sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal (OR, 15.5; 95% CI, 11.0 to 21.9), and
penile cancer (OR, 1.8; 95% CI, 0.9 to 3.7). Lesbian or bisexual women were over-represented
among women with oropharyngeal cancer (OR, 3.2; 95% CI, 1.7 to 6.0).
Conclusion
Large-scale evidence indicates that the distribution of cancer sites does not vary substantially by
sexual orientation, with the exception of some HPV- and HIV-associated cancers. These findings
highlight the importance of HPV vaccination in heterosexual and sexual minority populations.
J Clin Oncol 35:3654-3661. © 2017 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Over the last 30 years, there has been substantial
research efforts in the area of the health of sexual
minority populations; however, this research has
focused on sexually transmitted diseases, particu-
larly HIV,1,2 and little is known about how cancer
risk varies among sexual minorities compared with
heterosexual populations.2-4 This contrasts with the
increasing disease burden that is associated with
cancer, which is currently the leading cause of death
in high-income countries,5 and, after mental health
services and circulatory diseases, cancer services
make up the third largest category of spending in
contemporary health care systems.6
Approximately four of 10 cancers are attrib-
utable to lifestyle and environmental risk factors,
including smoking, alcohol consumption, dietary
factors, occupational exposures, and sexual and re-
productive history.7-9 Disparities in cancer incidence
among people from sexual minorities compared
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with heterosexual populations are likely. Lifetime exposure to risk
factors among sexual minority and heterosexual populations is likely
to differ—for example, smoking initiation is higher among lesbian,
gay, and bisexual young people in both the United Kingdom10 and
the United States.11 Hormonal factors are also likely to be important
for some cancers; child bearing and the use of oral contraceptives are
associated with a risk of female breast and ovarian cancer,12 and
lesbian and heterosexual women are differently exposed to these two
factors.13 In addition, HIV prevalence in the United Kingdom is
0.2%, but amongmenwho have sex withmen (age 15 to 44 years), it
is 5%14; immune deficiency is associated with an increased risk
of several cancers.15,16 Approximately 4.8% of cancer diagnoses
worldwide in 2008 were attributable to human papillomavirus
(HPV), with differences in exposure burden in men and women.17
Understanding how the risk of cancer varies by sexual orientation is
therefore of particular importance to help understand where best to
target preventive efforts.
In the United States, the Institute of Medicine in 2011 called
for research investment in the health of sexual minorities, in-
cluding basic epidemiologic research, which highlighted the lack of
relevant evidence.18 Similarly, ASCO has called for research on
sexual orientation–related disparities and increased data collec-
tion.19 In the United Kingdom. cancer charities have highlighted
the continuing limitations of data on lesbian, gay, and bisexual
people with cancer.20
It is usually difficult to study sexual orientation in population
health and epidemiologic studies, primarily because this in-
formation is simply not known or not collected.19 Nonetheless,
provided that items on sexual orientation are included, patient
experience surveys provide unique opportunities for acquiring
insight into the risk of cancer in sexual minorities.21
Against this background, we used data from two English
patient surveys, the General Practice Patient Survey (GPPS) and the
Cancer Patient Experience Survey (CPES), to examine two research
Table 1. Cancer Diagnosis Frequency and Unadjusted and Adjusted Percentages of Cancer Patient Experience Survey Responders Reporting Lesbian or Bisexual
Sexual Orientation by Cancer Site (women)
Cancer All Women, No. Lesbian/Bisexual Women, No. (unadjusted %)* Adjusted %†
All 131,073 920 (0.7) 0.7
Oropharyngeal (C01, C09, C10) 435 10 (2.3) 2.1
Oral (C02, C03, C04, C05) 569 , 6 0.8
Parotid/salivary (C07, C08) 112 , 6
Esophageal (C15) 1,317 , 6 0.3
Stomach (C16) 950 10 (1.1) 1.5
Small intestine (C17) 246 , 6 0.5
Colon (C18) 7,644 29 (0.4) 0.5
Rectal (C19, C20) 4,262 15 (0.4) 0.4
Anal (C21) 566 , 6 0.2
Liver (C22) 439 , 6 0.3
Gallbladder (C23) 107 , 6 1.3
Pancreatic (C25) 1,075 9 (0.8) 1.1
Laryngeal (C32) 198 , 6 0.7
Lung (C33, C34) 5,873 30 (0.5) 0.7
Bone sarcoma (C40, C41) 252 , 6 0.8
Melanoma (C43) 2,977 20 (0.7) 0.6
Mesothelioma (C45) 254 , 6 2.4
Kaposi’s sarcoma (C46) 8 0 (0.0)
Soft tissue sarcoma (C49) 441 , 6 0.4
Breast (C50) 48,296 382 (0.8) 0.7
Vulval/vaginal (C51, C52) 812 , 6 0.4
Cervical (C53) 1,462 19 (1.3) 0.7
Endometrial (C54, C55) 5,163 52 (1.0) 1.3
Ovarian (C56) 6,402 47 (0.7) 0.8
Renal (C64) 1,169 , 6 0.5
Ureteric (C65, C66) 272 , 6 1.4
Bladder (C67) 4,565 22 (0.5) 0.8
Brain (C71) 698 6 (0.9) 0.5
Thyroid (C73) 1,302 13 (1.0) 0.6
Cancer of unknown primary (C77, C78, C79, C80) 10,330 61 (0.6) 0.6
Hodgkin lymphoma (C81) 895 18 (2.0) 1.1
Non-Hodgkin lymphoma (C82, C83, C85) 7,312 54 (0.7) 0.9
Multiple myeloma (C90) 5,198 24 (0.5) 0.7
Leukemia (C91, C92, C93, C94, C95) 3,378 26 (0.8) 0.8
Ductal carcinoma in situ (D05) 3,311 20 (0.6) 0.5
All other 2,783 22 (0.8) 0.9
*Cells with fewer than six observations are suppressed in the reporting of crude counts and percentages, but are included in all multivariable analyses, including the
estimation of adjusted percentages.
†These percentages are predicted from multivariable logistic regression models to give the percentage of women with cancer at a particular site who are expected to
report lesbian/bisexual sexual orientation, should they have the same age composition as all included survey responders with this cancer diagnosis (this percentage is
also known as a recycled prediction). Odds ratios and 95% CI from this model are presented in Fig 1. Parotid/salivary cancer and Kaposi’s sarcoma are excluded from
multivariable analysis in women because small numbers of individuals led to perfect prediction in the multivariable models, and adjusted percentages are not presented.
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questions: Do women and men from sexual minorities report
a cancer diagnosis in the previous 5 years more or less frequently
than heterosexual women and men? And, among recently treated
survivors of cancer, is there variation between cancer sites in the
proportion of men and womenwho report gay, lesbian, or bisexual
sexual orientation?
PATIENTS AND METHODS
Data
GPPS is a national survey of the patient experience of primary care
and is sent by postal mail to approximately 2.7 million patients in England
age $ 18 years who have been continuously registered with a general
practice for at least 6 months, with a respondent sample of approximately
1 million (response rate approximately 37%). A stratified sample of
patients was drawn from the practice list of each general practice in
England, with oversampling of patients from practices that were known
from prior surveys to have low response rates. Full details are published
in the technical report.22 Data from 2011/2012 were used in this analysis.
Data from GPPS have been previously used to describe the patient
experience, health-related quality of life, and health service utilization of
sexual minorities.23,24
CPES is a separate survey of recently treated survivors of cancer25 that
is sent annually to all patients age$ 16 years who were treated for cancer in
a National Health Service hospital in England during a 3-month period.
Anonymous data from 2010, 2011/2012, 2013, and 2014 were obtained via
the UK Data Archive, and full survey details are available.26-29
This study involved the secondary analysis of previously collected
anonymous data, for which formal ethical approval is not required.30 All
cancer diagnoses are included in this analysis; however, cells counts of
fewer than six individuals are suppressed in reporting, which is in line with
best practice.31
Overall and Site-Specific Diagnosis of Cancer
In the GPPS, respondents are asked “Which, if any, of the following
medical conditions do you have?,” with 16 response options, including
“Cancer in the last 5 years,” plus “None of these conditions” and “I would
prefer not to say”. “Prefer not to say” responses and responses for which no
options were ticked were coded as missing for this analysis. No additional
detail about the nature of the cancer diagnosis—that is, in relation to
cancer site—is available in this survey.
In CPES, patients were identified for inclusion in the survey sampling
frame when the main hospital record for inpatient or outpatient treatment
recorded an International Classification of Diseases, Tenth Revision cancer
diagnosis code for inpatient or outpatient cancer treatment. In line with
previous research,32 but with the addition of Kaposi’s sarcoma,we included 38
common and rarer cancer site groups in the analysis (Table A8, online-only).
Sexual Orientation
Survey questions were used to identify respondents’ sexual orien-
tation in both surveys. In GPPS, “Which of the following best describes
how you thinkof yourself?” had the following possible responses: “Heterosexual/
straight,” “Gay/Lesbian,” “Bisexual,” “Other,” or “I would prefer not to say”.
In CPES, “Which of the following best describes your sexual orientation?”
has the following possible responses: “Heterosexual/straight (opposite sex),”
“Bisexual (both sexes),” “Gay or Lesbian (same sex),” “Other,” of “Prefer not
to answer.”
Demographic Information
In GPPS, survey responses for age 18 to 24 years, then 10-year age
groups to age $ 85 years, gender, and ethnicity in five groups (ONS2011)
were used. In CPES, hospital record recorded age and gender (as these are
more complete), and survey-reported ethnicity in six groups (ONS2001)
were used. For both surveys, the Index of Multiple Deprivation—a small
geographic area measure of socioeconomic deprivation, derived from
respondents’ postcodes—was used and divided into five groups by using
quintile-defining cut points.33
Analysis
In all analyses, women and men are considered separately, and all
respondents—both those from sexual minorities and those who report
heterosexual sexual orientation—are included. GPPS survey data are
provided with weights that account for design and nonresponse22;
therefore, descriptive analysis is presented for weighted data. For CPES, as
all cancer cases within the sampling period were selected, design weights
are not applicable, and only unweighted data are presented.
For our first analysis, using data from GPPS we performed logistic
regression to examine variations in report of cancer diagnosis in the last
5 years by sexual orientation, including a test of any difference between gay
or lesbian and bisexual individuals.
For the second analysis, we used data from recently treated survivors
of cancer who responded to CPES with sexual orientation as a binary
outcome—grouping gay or lesbian and bisexual respondents—and cancer
Table 2. Cancer Prevalence by Sexual Orientation Among GPPS Responders
GPPS Unadjusted/Crude Adjusted for Age
Sexual Orientation
All Respondents,
No. (%)*
Respondents Who Report Having Had
Cancer in the Last 5 Years, No. (%)*
Odds Ratio
(95% CI) P
Odds Ratio
(95% CI) P
All 796,594 32,437
Women 445,469 (50.4) 16,094 (49.2)
Men 351,125 (49.6) 16,343 (50.8)
Women
Heterosexual 440,698 (98.6) 15,982 (99.2) Reference , .001 Reference .19
Lesbian 2,759 (0.6) 76 (0.5)
0.64 (0.53 to 0.77) 1.14 (0.94 to 1.37)
Bisexual 2,012 (0.7) 36 (0.3)
Men
Heterosexual 343,719 (97.2) 16,094 (98.2) Reference , .001 Reference , .001
Gay 5,584 (1.6) 187 (1.5) 0.71 (0.61 to 0.82) 1.45 (1.24 to 1.69)
Bisexual 1,822 (0.5) 62 (0.4) 0.72 (0.56 to 0.92) 1.00 (0.78 to 1.30)
Abbreviation: GPPS, General Practice Patient Survey.
*These percentages are weighted to the population.
3656 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Saunders et al
Downloaded from ascopubs.org by 144.173.43.50 on February 7, 2019 from 144.173.043.050
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
site as covariate. This analysis aimed to reveal overall patterns of variation
between cancer sites in the proportion of men and women who report
gay, lesbian, or bisexual sexual orientation. For a particular cancer site,
higher or lower odds reflect differences in cancer diagnosis among people
from sexual minorities compared with the reference site (breast in
women, prostate in men). Our choice of these reference sites was based
on analytical considerations—that is, because they were the cancers with
the largest sample size, which allowed the most precise comparisons. In
addition, from these models, we predicted the adjusted percentage of
women and men with cancer of a particular site who were expected to
report lesbian or bisexual or gay or bisexual sexual orientation should
they have the same age composition as all included survey responders
with this diagnosis (this percentage is also known as a recycled
prediction).
Adjusting for ethnicity, deprivation, survey wave (CPES), and GP
practice (GPPS) or hospital of treatment (CPES; using a random effect for
organization) had a minimal effect on coefficients for cancer site, and,
given this, to reduce the amount of missing observations as a result of
incomplete information on deprivation and ethnicity, these variables were
dropped from the main analyses, which are only adjusted for age (Ap-
pendix Tables A1 to A3, online only).
Supplementary Analyses
We explored a series of sensitivity analyses. First, we considered each
response option to the sexual orientation question separately—that is,
“Gay/Lesbian,” “Bisexual,” “Other,” “I would prefer not to say,” andmissing
responses were compared with the response, “Heterosexual/straight,” to
examine potential associations between our outcomes and patient groups
other than those that endorsed heterosexual, gay/lesbian, and bisexual
response options. Second, for CPES analysis, we also restricted the analysis
to people who had been diagnosed with cancer in the past year to consider
a population that more closely represented incident cancer cases34 and to
explore the potential impact of the same respondents being included across
survey waves.
RESULTS
Among 796,594 respondents from the population-based GPPS
sampling frame, 32,437 of all respondents (3.0%) reported cancer
in the past 5 years. Of the 12,177 respondents (2.1%) from sexual
Table 3. Cancer Diagnosis Frequency and Unadjusted and Adjusted Percentages of Cancer Patient Experience Survey Responders Reporting Gay or
Bisexual Sexual Identity by Cancer Site (men)
Cancer All Men, No. Gay/Bisexual Men, No. (unadjusted %)* Adjusted %†
All 117,937 1,279 (1.1) 1.1
Oropharyngeal (C01, C09, C10) 1,393 17 (1.2) 0.9
Oral (C02, C03, C04, C05) 821 14 (1.7) 1.4
Parotid/salivary (C07, C08) 151 , 6 1.2
Esophageal (C15) 3,735 44 (1.2) 1.2
Stomach (C16) 2,534 15 (0.6) 0.6
Small intestine (C17) 350 , 6 1.0
Colon (C18) 10,048 99 (1.0) 1.1
Rectal (C19, C20) 8,072 76 (0.9) 0.9
Anal (C21) 278 48 (17.3) 15.7
Liver (C22) 1,012 7 (0.7) 0.7
Gallbladder (C23) 43 , 6
Pancreatic (C25) 1,229 16 (1.3) 1.3
Laryngeal (C32) 1,029 10 (1.0) 0.9
Lung (C33, C34) 7,070 63 (0.9) 1.0
Bone sarcoma (C40, C41) 352 6 (1.7) 0.9
Melanoma (C43) 2,843 43 (1.5) 1.3
Mesothelioma (C45) 1,111 6 (0.5) 0.6
Kaposi’s sarcoma (C46) 28 13 (46.4) 35.4
Soft tissue sarcoma (C49) 578 7 (1.2) 0.9
Breast (C50) 345 , 6 1.3
Penile (C60) 331 8 (2.4) 2.3
Prostate (C61) 20,783 224 (1.1) 1.3
Testicular (C62) 1054 26 (2.5) 0.9
Renal (C64) 2,314 30 (1.3) 1.2
Ureteric (C65, C66) 483 , 6 0.8
Bladder (C67) 16,687 136 (0.8) 1.0
Brain (C71) 1,045 22 (2.1) 1.1
Thyroid (C73) 560 14 (2.5) 1.6
Cancer of unknown primary (C77, C78, C79, C80) 6,362 61 (1.0) 1.0
Hodgkin lymphoma (C81) 992 29 (2.9) 1.4
Non-Hodgkin lymphoma (C82, C83, C85) 8,520 81 (1.0) 0.9
Multiple myeloma (C90) 7,304 67 (0.9) 1.0
Leukemia (C91, C92, C93, C94, C95) 5,674 47 (0.8) 0.7
Ductal carcinoma in situ (D05) 17 , 6
All other 2,789 36 (1.3) 1.2
*Cells with fewer than six observations are suppressed in the reporting of crude counts and percentages, but are included in all multivariable analyses, including the
estimation of adjusted percentages.
†These percentages are predicted frommultivariable logistic regressionmodels to give the percentage ofmenwith cancer at a particular site who are expected to report
gay/bisexual sexual orientation, should they have the same age composition as all included survey responders with this cancer diagnosis (this percentage is also known
as a recycled prediction). Odds ratios and 95%CI from thismodel are presented in Fig 2. Gallbladder and ductal carcinoma in situ are excluded frommultivariable analysis
in men because small numbers of individuals led to perfect prediction in the multivariable models.
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minorities, 361 (1.9%) reported cancer in the past 5 years. Among
the 240,010 recently treated survivors of cancer who responded to
CPES between 2010 and 2014, there were 2,199 respondents
(0.9%) who endorsed a sexual minority orientation.
Before adjustment for age, people from sexual minorities are
less likely to report cancer in the past 5 years, as, on average, people
who report nonheterosexual sexual orientation are younger than
those who report heterosexual sexual orientation.23 After adjusting
for age, GPPS data provided no evidence of a difference between
heterosexual and lesbian or bisexual women (odds ratio [OR],
1.14; 95% CI, 0.94 to 1.37; P = .19); however, gay or bisexual men
were more likely to report cancer in the past 5 years than het-
erosexual men (OR, 1.31; 95% CI, 1.15 to 1.50; P , .001), with
evidence of a difference between gay (OR, 1.45; 95% CI, 1.24 to
1.69) and bisexual men (OR, 1.00; 95% CI, 0.78 to 1.30; Table 2).
Although lesbian or bisexual women represented 0.7% of all
female CPES responders (any cancer site), they represented 2.3%
(adjusted, 2.1%) of women with oropharyngeal cancer, 2.0%
(adjusted, 1.1%) with Hodgkin lymphoma, and 1.3% (adjusted,
0.7%) of women with cervical cancer. In the same way, although
gay or bisexual men represented 1.1% of all male CPES responders
(any cancer site), they made up 46.4%(adjusted, 35.4%) of men
with Kaposi’s sarcoma, 17.3% (adjusted, 15.7%) of men with anal
cancer, 2.9% (adjusted, 1.4%) of men with Hodgkin lymphoma,
2.5% (adjusted, 0.9%) of men with testicular, and 2.5% (adjusted,
1.6%) thyroid cancers. Again, because endorsing a sexual mi-
nority orientation in the two surveys was more common in
younger patients,23 crude figures are confounded by age, with the
crude proportions of men and women from sexual minorities
higher for cancer sites where diagnosis among young people is
more common—for example, cervical and testicular cancer, and
Hodgkin Lymphoma (Tables 1 and 3).
After adjusting for age, there continues to be statistical evi-
dence that the proportion of people from sexual minorities varies
between cancer sites (women, P= .0002; men, P, .0001).Whereas
evidence for overall variation is statistically significant, the number
of cases for many sites is small, which resulted in wide CIs (Figs 1
and 2). For most cancer sites that were examined in our adjusted
analysis (30 of 33 in women, 28 of 32 in men), there was no
evidence that sexual minorities were over- or under-represented
compared with the most common cancers in each gender (female,
breast; male, prostate); however, there were a few notable differ-
ences, including some infection-related (HIV or HPV) cancers.
Lesbian/bisexual women are more frequently represented among
women with oropharyngeal cancer (OR, 3.2; 95% CI, 1.7 to 6.0),
and less frequently represented in anal (OR, 0.3; 95% CI, 0.0 to
2.0), and vulval/vaginal cancers (OR, 0.7; 95% CI, 0.2 to 2.1),
although CIs are wide. Gay or bisexual men are relatively more
frequently represented among men with Kaposi’s sarcoma (OR,
48.2; 95% CI, 22.0 to 105.6), anal (OR, 15.5; 95% CI, 11.0 to 21.9),
and penile cancer (OR, 1.8; 9% CI, 0.9 to 3.7). In addition, lesbian
or bisexual women are more frequently represented among women
with mesothelioma, stomach, and endometrial cancers, but less
among liver and esophageal cancers. Gay or bisexual men are more
frequently represented among men with thyroid and oral cancers,
melanoma, and Hodgkin lymphoma, and are relatively less fre-
quently represented in liver and stomach cancers, leukemia, and
mesothelioma.
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Fig 1. Odds ratios of specific cancer site
diagnosis by lesbian or bisexual orientation
amongwomenwith cancer, adjusted for age
(Cancer Patient Experience Survey). Diagnoses
represented with gold circles indicate fewer
than six womenwith this diagnosis reporting
lesbian or bisexual sexual identity (CPES);
these diagnoseswere included in the analysis
model in the same way as other cancers,
however the gold circles highlight that these
results are based on relatively small numbers
of cases.
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In supplementary analyses, self-reported cancer prevalence
among GPPS responders was lower among women with a missing
response regarding their sexual orientation (P = .027) and men
who stated, “Prefer not to say” (P , .001), with a small but
significant (men, P = .0005; women, P = .001) variation in missing
responses by cancer site, and “Prefer not to say” (men, P , .001).
Considering respondents who had been diagnosed only in the past
year, findings were consistent with the main analyses of CPES
respondents. Variation in cancer diagnosis was also consistent
when considering gay or lesbian and bisexual CPES responders
separately (Appendix Tables A4 to A6, online only).
DISCUSSION
We report large-scale evidence from two nationwide patient sur-
veys in England, including information on self-reported sexual
orientation, to explore whether women and men from sexual
minorities report a cancer diagnosis in the previous 5 years more or
less frequently than heterosexual women and men, and, among
recently treated survivors of cancer, whether there is variation
between cancer sites in the proportion of men and women who
report gay, lesbian, or bisexual sexual orientation. We find that gay
or bisexual men are more likely to have had cancer in the past 5
years than heterosexual men of the same age, although there was no
evidence of a difference in cancer prevalence between heterosexual
and lesbian or bisexual women. For both men and women, sexual
orientation seems to be unrelated to the diagnosis of most cancer
sites, particularly the more common cancers, but sexual minorities
are over- or under-represented among patients of certain rarer
sites. Cancer sites associated with HPV—and HIV—infection are
those with the greatest degree of variation in the proportion of men
and women from sexual minorities.
Regarding cancer prevalence, against limited overall evidence,
our findings are consistent with a single other similar source, which
also found similar cancer prevalence among heterosexual and
sexual minority women, but increased odds among gay and bi-
sexual men compared with heterosexual men.35 With regard to
HPV-associated cancers, increased prevalence of anal cancer
among gay men has been previously described36; however, to our
knowledge, the relative over-representation of lesbian and bisexual
women among women with oropharyngeal cancer has not pre-
viously been described and constitutes a novel finding. A history of
performing oral sex is a known risk factor for oropharyngeal
cancer.37 Previous evidence indicates that there is a higher
probability of HPV transmission via vaginal oral sex compared
with penile oral sex,38,39 which would result in a higher burden of
oral HPV infection among lesbian and bisexual women.
Cervical cancer is associated with HPV infection, yet we do
not find that lesbian or bisexual women are under-represented
among womenwith cervical cancer. Our findings may be explained
by a relatively low uptake of screening40-42 plus an earlier initiation
of sexual intercourse.43 There have been inconsistent messages in
the past about whether lesbian women need to attend cervical
screening programs,20,40 but our data do not suggest any reduced
need.
There are also some unexpected differences in cancer di-
agnosis by sexual orientation, in particular, the excess risk of
mesothelioma and stomach cancer in lesbian women. Here, our
findings may add novel insights, although with the caution that
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Fig 2. Odds ratios of specific cancer site
diagnosis by gay or bisexual orientation among
men with cancer, adjusted for age.
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numbers are relatively low. Nonetheless, differences by sexual
orientation among women with regard to occupational exposures,
smoking (contributing to cancer risk across several sites), or di-
etary factors may be important, although this is speculative. The
higher risk of endometrial cancer among lesbian or bisexual
women is also surprising and is inconsistent with prior evidence.44
There are limitations that are inherent in all survey research,
and, in this study, one such limitation is that the CPES analysis is
based on treated patients, rather than population-based incident
cases, and so rates cannot be estimated; however, our sensitivity
analysis using only cases diagnosed in the last year—more similar
to an incident population34—provided results that were consistent
with the main analyses presented. Additional strengths of our study
are its large analyses samples, the examination of both common
and rare cancer sites, and the use of well-characterized national
survey data.25,45-48
Although response rates for CPES are high (64% to 67%),
response rates for GPPS were 37%; however, response rates alone
are a poor indicator of bias.49 In addition, a randomized controlled
trial demonstrated no variation in GPPS response rates when
a question about the sexual orientation of the participant was
included or excluded; this does not exclude, but greatly mitigates,
the potential for survey nonparticipation bias by sexual
orientation.45
We acknowledge that some people who identify as lesbian, gay,
or bisexual may be unwilling to acknowledge their identity in
a survey50; increased homelessness among young lesbian, gay, and
bisexual people in the United Kingdom may also lead to additional
under-representation among survey responders.51 In addition,
item nonresponse is another concern, with people who do not
respond to the sexual orientation question at all (in GPPS) possibly
also being less likely to report any long-term conditions. People
who report greater concerns about privacy are less likely to respond
to sensitive demographic survey questions,52 and it is likely that the
same mechanism may apply in our study context.
Sexual orientation and sexual behavior are different constructs;
in this work, we consider cancer diagnosis associated with sexual
orientation, althoughwe acknowledge that HPV infection–associated
cancer risk is primarily related to sexual behavior. The survey in-
struments encompassed heterosexual, gay, lesbian, and bisexual
orientation, which is consistent with survey questions that were
developed and validated by the UKOffice of National Statistics53
that, however, do not encompass all sexual orientation and
gender identity groups.
HPV vaccination presents an important opportunity for
cancer prevention.43 In the United Kingdom, the current vacci-
nation program covers girls age 12 to 13 years, and a recent pilot
HPV vaccination schedule for men who have sex with men was
rolled out in 2016.54 Modeling work is still in progress to decide
whether all boys should receive the vaccination at age 12 to 13 years
alongside girls.55 The research presented here provides additional
epidemiologic evidence to inform decisions about the most eq-
uitable, effective, and cost-effective HPV vaccination schedules.
Evidence from the United States suggests that HPV vaccination
rates among lesbian women are low.56 Our research provides
additional evidence that should particularly support efforts to
encourage vaccination among lesbian and bisexual women.
This work presents population-based evidence about cancer
prevalence among men and women from sexual minorities and
about the relative frequencies of people from sexual minorities
with common and rarer cancer diagnoses among recently treated
survivors of cancer. Demographic data on cancer among people
from sexual minorities are scarce20; these findings begin to address
this evidential need. Finally, our research also highlights the im-
portance of HPV vaccination among gay, lesbian, and bisexual
women and men.
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Appendix
Appendix Tables A1 to A3
In the main analyses presented in this article, we adjust only for age as a categorical variable. We also consider as possible
confounders race and ethnicity, an additional age term, socioeconomic inequalities, survey wave (year), and hospital/general
practice of treatment. As including these variables did not change the magnitude of the effect sizes of the association between sexual
orientation and cancer diagnosis—results presented in Appendix Table A1 for General Practice Patient Survey (GPPS) and
Appendix Tables A2 and A3 for Cancer Patient Experience Survey (CPES)—we did not include them in the final analysis models,
which were presented only adjusted for age and stratified by sex. In addition, including additional covariates in our analysis models
led to issues with smaller sample sizes—deprivation and ethnicity information is missing for some respondents—and issues of
perfect prediction for some rarer cancer site diagnoses. Although the final analysis models are therefore parsimonious, unmeasured
confounding is not expected to be a major concern.
The only coefficient that does change is that for Kaposi’s sarcoma in men after adjusting for hospital (reduction from 48.5 to
19.2; Appendix Table A3). Even after adjustment, this remains the cancer diagnosis with the strongest association with sexual
orientation, and reflects the fact that patients with Kaposi’s sarcoma were only treated in a small number of hospitals overall, rather
than more general confounding by region, and do not change the overall conclusions of this work. As we are interested in
population-level estimates, rather than within-hospital estimates, in this analysis, we did not include this random effect in the final
model.
Appendix Tables A4 to A6
Survey questions were used to identify respondents’ sexual orientation in both surveys. In GPPS, “Which of the following best
describes how you think of yourself?” had the following possible responses: “Heterosexual/straight,” “Gay/Lesbian,” “Bisexual,”
“Other,” or “I would prefer not to say.” In CPES, “Which of the following best describes your sexual orientation?” had the following
possible responses: “Heterosexual/straight (opposite sex),” “Bisexual (both sexes),” “Gay or Lesbian (same sex),” “Other,” or “Prefer
not to answer.” To explore the sensitivity of our findings to different response options, we investigated the associations between each
of the sexual orientation response options and the overall and site-specific diagnoses of cancer in a series of analyses. In particular, in
the CPES analyses, the models for which the responses, “Bisexual” and “Gay” or “Lesbian,” are not grouped are consistent with the
main analyses presented here, although CIs are wider, and variability in effect sizes are likely to reflect this imprecision.
Appendix Table A5
Results from the main analysis model (presented in Fig 1) are presented in column 1 in this table. Additional analyses explore
whether there is any variation between cancer sites in the proportion of women who report “Other” or “Prefer not to say” sexual
orientation, or who do not respond to this question at all, and can be compared with the findings from the main model. Although
there is evidence that the proportion of women who did not respond to the sexual orientation question varies between cancer sites,
the magnitude of these differences are small (all odds ratios are close to 1), particularly compared with the variation in the main
model
Appendix Table A6
Although from these analyses there is evidence that the proportion of men who responded with the “Prefer not to say” option
or who did not respond to the sexual orientation quesiont varies between cancer sites, the magnitude of these differences are small
(all odds ratios are close to 1), particularly compared with the variation in the main model. Men with anal cancer have 2.4 times
greater odds of giving a “Prefer not to say” response to the survey question about sexual identity than men with prostate cancer, and
men with Kaposi’s sarcoma have 11.0 times greater odds of giving a “Prefer not to say” response. Clearly, there is some increased use
of the “Prefer not to say” option among gay or bisexual men with these diagnoses, but it is not possible to determine the extent to
which this option is used more frequently by all gay or bisexual men, or whether this is particularly related to these diagnoses that
perhaps have greater stigma attached.
Appendix Tables A7 and A8
These tables present details of the sample derivation and clinical coding of cancer sites used in the main analysis.
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Notes to Support the Comparison of Results From Tables 1 to 3
In Table 2, this analysis uses data from the GPPS to answer the research question, “Do women and men from sexual minorities
report a cancer diagnosis in the previous 5 years more or less frequently than heterosexual women and men?”
In Tables 1 and 3, the CPES is used to explore the question, “Among recently treated survivors of cancer, is there variation
between cancer sites in the proportion of men and women who report gay, lesbian, or bisexual sexual orientation?”
GPPS data are a population-based sample of the population of England, and we can therefore estimate cancer prevalence
among men and women from sexual minorities—with and without cancer in the past 5 years—and compare this with people who
report a heterosexual sexual orientation. This is a unique data source, as the large sample size—nearly 1 million people—and the
availability of sampling and design weights allow us to estimate cancer prevalence in the last 5 years in England, stratified by sexual
orientation, then adjusted for age. These results are presented in Table 2.
CPES data are also a unique survey resource of recently treated survivors of cancer, sent annually to all patients age$ 16 years.
The strengths of this data resource are the large number of people with cancer—249,010 patients, including 920 lesbian or bisexual
women and 1,279 gay or bisexual men (these numbers of people from sexual minorities with cancer are much higher compared
with the population-based GPPS sample, which includes both people with and without cancer—and the availability of specific
International Classification of Diseases, Tenth Revision, diagnosis codes, which are not available for the GPPS data; however, the
two limitations in the CPES data are, first, the sample is hospital based, rather than population based (recently treated survivors of
cancer), and, second, that we do not have a comparison population of people without cancer. This means that we cannot estimate
cancer prevalence by using the CPES data. Instead, it is possible to estimate whether there is variation between cancer sites in the
proportion of men and women who report gay, lesbian, or bisexual sexual orientation by using a case-only analysis.
These proportions allow us to explore whether people from sexual minorities are relatively over- or under-represented among
people with a particular cancer diagnosis compared with baseline diagnosis—that is, are there more people from sexual minorities
with a particular cancer site diagnosis than would be expected were there no variation between sites? This over- or under-
representation will reflect higher or lower incidence, or higher or lower survival, among people from sexual minorities, but
incidence and prevalence cannot be measured directly, and the comparison is therefore between cancer sites, rather than with
people without cancer.
In practical terms, this means for the analysis that results in Tables 1 to 3 are complementary but not directly comparable, as the
populations and the analyses are different. In Table 2, results tell us about cancer prevalence in the whole population of England
(age$ 18 years)—that prevalence is higher among gay or bisexual men, but not among lesbian or bisexual women. In Tables 1 and 3,
results tell us about variation between cancer sites, but not about comparisons with the whole population.
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Table A1. Exploration of Potential Confounders in the Relationship Between Cancer Prevalence and Sexual Orientation (General Practice Patient Survey)
Variable Sexual Orientation
OR for Reporting Cancer in the
Last 5 Years (95% CI) P
Women
Unadjusted Heterosexual Reference , .001
Lesbian/bisexual 0.64 (0.53 to 0.77)
Adjusted for age Heterosexual Reference .19
Lesbian/bisexual 1.14 (0.94 to 1.38)
Adjusted for deprivation (n = 445,185) Heterosexual Reference .17
Lesbian/bisexual 1.14 (0.95 to 1.38)
Adjusted for age only (on deprivation sample for comparison) Heterosexual Reference .18
Lesbian/bisexual 1.14 (0.94 to 1.38)
Adjusted for ethnicity (n = 442,818) Heterosexual Reference .14
Lesbian/bisexual 1.15 (0.95 to 1.40)
Adjusted for age only (on deprivation sample for comparison) Heterosexual Reference .17
Lesbian/bisexual 1.14 (0.95 to 1.38)
Adjusted for region/GP practice Heterosexual Reference .19
Lesbian/bisexual 1.14 (0.94 to 1.37)
Men
Unadjusted Heterosexual Reference , .001
Gay/bisexual 0.71 (0.62 to 0.80)
Adjusted for age Heterosexual reference , .001
Gay/bisexual 1.31 (1.15 to 1.49)
Adjusted for deprivation (n = 445,185) Heterosexual Reference , .001
Gay/bisexual 1.33 (1.17 to 1.51)
Adjusted for age only (on deprivation sample for comparison) Heterosexual Reference , .001
Gay/bisexual 1.31 (0.15 to 1.50)
Adjusted for ethnicity (n = 442,818) Heterosexual Reference , .001
Gay/bisexual 1.30 (0.13 to 1.48)
Adjusted for age only (on deprivation sample for comparison) Heterosexual Reference , .001
Gay/bisexual 1.29 (0.13 to 1.47)
Adjusted for region/GP practice Heterosexual Reference , .001
Gay/bisexual 1.31 (1.15 to 1.49)
Abbreviations: GP, general practice; OR, odds ratio.
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Table A4. Cancer Prevalence and Alternative Response Options to the Sexual Orientation Question in Women and Men (General Practice Patient Survey)
Variable Sexual Orientation OR for Reporting Cancer in the Last 5 Years (95% CI) P
Women
Adjusted for age Heterosexual Reference .19
Lesbian/bisexual 1.14 (0.94 to 1.38)
Considering lesbian women only Heterosexual Reference .097
Lesbian 1.22 (0.96 to 1.53)
Considering bisexual women only Heterosexual Reference .99
Bisexual 1.00 (0.72 to 1.40)
Considering both groups separately Heterosexual Reference .25
Lesbian 1.22 (0.96 to 1.53)
Bisexual 1.00 (0.72 to 1.40)
“Other” responses Heterosexual Reference .38
“Other response” 0.90 (0.72 to 1.13)
“Prefer not to say” Heterosexual women Reference .18
“Prefer not to say” 0.95 (0.88 to 1.02)
Missing response Heterosexual Reference .027
Item nonresponse 0.94 (0.89 to 0.99)
Men
Adjusted for age Heterosexual Reference , .001
Gay/bisexual 1.31 (1.15 to 1.49)
Considering gay men only Heterosexual Reference , .001
Gay 1.45 (1.25 to 1.69)
Considering bisexual men only Heterosexual Reference .95
Bisexual 1.01 (0.78 to 1.31)
Considering both groups separately Heterosexual Reference , .001
Gay 1.45 (1.25 to 1.69)
Bisexual 1.01 (0.78 to 1.31)
“Other” responses Heterosexual Reference .10
“Other response” 0.82 (0.65 to 1.04)
“Prefer not to say” Heterosexual Reference , .001
“Prefer not to say” 0.79 (0.73 to 0.86)
Missing response Heterosexual Reference .130
Item nonresponse 0.95 (0.89 to 1.02)
Abbreviation: OR, odds ratio.
© 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Saunders et al
Downloaded from ascopubs.org by 144.173.43.50 on February 7, 2019 from 144.173.043.050
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
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Table A7. GPPS and CPES Survey Responses Flowchart
Survey
Survey Year
2010 2011/2012 2013 2014
GPPS
Responses received 1,037,946
Valid response to the question about long-term health conditions (cancer) 906,578
Response to the question about gender 891,707
Response to the question about age 884,966
Response to the question about sexual orientation 838,083
Excluding responses “Other” and “Prefer not to say” 796,594
Included responses 796,594
CPES
Responses received 67,713 71,793 68,737 70,141
Total responses 278,384
Single gender cancer diagnoses/inconsistent gender exclusions* 278,332
Response to the question about sexual orientation 259,788
Excluding responses “Other” and “Prefer not to say” 249,010
Included responses 249,010
Responses included in multivariable models† 248,830
NOTE. All data are given as No.
Abbreviations: CPES, Cancer Patient Experience Survey; GPPS, General Practice Patient Survey.
*Cervical, 9 male; endometrial, 11 male; ovarian, 11 male; prostate, 21 female.
†Parotid/salivary cancer and Kaposi’s sarcoma are excluded from multivariable analysis in women because small numbers of individuals led to perfect prediction in the
multivariable models, and gallbladder and ductal carcinoma in situ are excluded from multivariable analysis in men for the same reason.
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Table A8. Cancer Diagnosis by ICD-10 Code
Cancer ICD-10 Code ICD-10 Code Description
Oropharyngeal C01, C09, C10 Malignant neoplasms of base of tongue (C01), tonsil (C09), and
oropharynx (C10)
Oral C02, C03, C04, C05 Malignant neoplasm of other and unspecified parts of tongue
(C02), gum (C03), floor of mouth (C04), and palate (C05)
Parotid C07, C08 Malignant neoplasm of parotid gland (C07) and other and
unspecified major salivary glands (C08)
Esophageal C15 Malignant neoplasm of esophagus
Stomach C16 Malignant neoplasm of stomach
Small intestine C17 Malignant neoplasm of small intestine
Colon C18 Malignant neoplasm of colon
Rectal C19, C20 Malignant neoplasm of recto-sigmoid junction (C19) and of
rectum (C20)
Anal C21 Malignant neoplasm of anus and anal canal
Liver C22 Malignant neoplasm of liver and intrahepatic bile ducts
Gallbladder C23 Malignant neoplasm of gallbladder
Pancreatic C25 Malignant neoplasm of pancreas
Laryngeal C32 Malignant neoplasm of larynx
Lung C33, C34 Malignant neoplasm of trachea (C33) and bronchus and lung
(C34)
Bone sarcoma C40, C41 Malignant neoplasm of bone and articular cartilage of limbs
(C40) and other and unspecified sites (C41)
Melanoma C43 Malignant melanoma of skin
Mesothelioma C45 Mesothelioma
Kaposi’s sarcoma C46 Kaposi sarcoma
Soft tissue sarcoma C49 Malignant neoplasm of other connective and soft tissue
Breast C50 Malignant neoplasm of breast
Vulval/vaginal C51, C52 Malignant neoplasm of vulva (C51) and vagina (C52)
Cervical C53 Malignant neoplasm of cervix uteri
Endometrial C54, C55 Malignant neoplasm of corpus uteri (C54) and of uterus,
unspecified (C55)
Ovarian C56 Malignant neoplasm of ovary
Penile C60 Malignant neoplasm of penis
Prostate C61 Malignant neoplasm of prostate
Testicular C62 Malignant neoplasm of testis
Renal C64 Malignant neoplasm of kidney, except renal pelvis
Ureteric C65, C66 Malignant neoplasm of renal pelvis (C65) and ureter (C66)
Bladder C67 Malignant neoplasm of bladder
Brain C71 Malignant neoplasm of brain
Thyroid C73 Malignant neoplasm of thyroid gland
Cancer of unknown primary C77, C78, C79, C80 Secondary and unspecified malignant neoplasm of lymph
nodes (C77); secondary malignant neoplasm of respiratory
and digestive organs (C78); secondary malignant neoplasm
of other and unspecified sites (C79); and malignant
neoplasm, without specification of site (C80)
Hodgkin lymphoma C81 Hodgkin lymphoma
Non-Hodgkin lymphoma C82, C83, C85 Follicular (nodular) non-Hodgkin lymphoma (C82), diffuse non-
Hodgkin lymphoma (C83), other and unspecified types of
non-Hodgkin lymphoma (C85)
Multiple myeloma C90 Multiple myeloma and malignant plasma cell neoplasms
Leukemia C91, C92, C93, C94, C95 Lymphoid leukemia (C91), myeloid leukemia (C92), monocytic
leukemia (C93), other leukemias of specified cell type (C94),
and other leukemias of unspecified cell type (C95)
Ductal carcinoma in situ D05 Carcinoma in situ of breast
All other diagnoses
Abbreviation: ICD-10, International Classification of Diseases, Tenth Revision.
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